Mephedrene‐Induced Cardiac Electrophysiological and Molecular Alterations: An Integrated In Vitro and In Vivo Study
Journal of Applied Toxicology · 2026
DOI: 10.1002/jat.70233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2026. Verfasst von Min Gyeong Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Sciences, Graduate School of Sungkyunkwan University (Natural Sciences Campus), Suwon, South Korea. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Methamphetamine, Central Nervous System Stimulants. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Korea, National Institute of Food and Drug Safety Evaluation.
Abstract (Originalsprache)
Mephedrene, a psychoactive stimulant structurally related to methamphetamine, has recently emerged on illicit markets. Although methamphetamine‐like compounds are known to stimulate the central nervous system and elevate cardiovascular risk, the pharmacological and toxicological characteristics of mephedrene, particularly its cardiotoxic potential, are poorly defined. Cardiotoxicity was evaluated using integrated in vitro and in vivo approaches. Human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) were assessed for electrophysiological alterations by multi‐electrode array (MEA) recordings, cell viability by WST‐1 assay, and sarco/endoplasmic reticulum Ca 2+ ‐ATPase 2 (SERCA2) expression by Western blotting. In vivo electrocardiography (ECG) was recorded in rats following intravenous mephedrene administration (5 or 15 mg/kg). WST‐1 assays revealed a significant decline in cell viability from 300 μM. MEA analysis showed reductions in Fridericia‐corrected field potential duration (FPDcF) and beat period at 10 μM and a decrease in spike amplitude at 50 μM. Western blots demonstrated SERCA2 downregulation at 50 and 100 μM, consistent with impaired Ca 2+ handling. In vivo, mephedrene produced significant QT interval prolongation at 5 and 15 mg/kg, with a dose‐dependent increase. This study provides the first integrated evidence that mephedrene induces concentration‐dependent disturbances in cardiac electrophysiology, viability, and Ca 2+ ‐regulatory mechanisms in vitro and prolongs QT intervals in vivo. These findings indicate substantial cardiovascular risk associated with mephedrene exposure and underscore the need for toxicological surveillance and regulatory action to mitigate potential public health harms posed by emerging novel psychoactive substances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Forensic Sciences, Graduate School of Sungkyunkwan University (Natural Sciences Campus), Suwon, South Korea.
- Pharmacological and Narcotics Research Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, South Korea.
ORCID-Profile: Min Gyeong Kim, Si-Keun Lim
Förderung
- National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Korea
- National Institute of Food and Drug Safety Evaluation
Zitieren
APA
Kim, M. G., Min, H. K., Lim, S. K., & Jung, K. K. (2026). Mephedrene‐Induced Cardiac Electrophysiological and Molecular Alterations: An Integrated In Vitro and In Vivo Study. Journal of Applied Toxicology. https://doi.org/10.1002/jat.70233
Vancouver
Kim MG, Min HK, Lim SK, Jung KK. Mephedrene‐Induced Cardiac Electrophysiological and Molecular Alterations: An Integrated In Vitro and In Vivo Study. Journal of Applied Toxicology. 2026. doi:10.1002/jat.70233
BibTeX
@article{Kim2026,
author = {Kim, Min Gyeong and Min, Hyun Kyu and Lim, Si-Keun and Jung, Ki Kyung},
title = {Mephedrene‐Induced Cardiac Electrophysiological and Molecular Alterations: An Integrated In Vitro and In Vivo Study},
journal = {Journal of Applied Toxicology},
year = {2026},
doi = {10.1002/jat.70233}
}
EUVIMED